PGRN Is Associated with Late-Onset Alzheimer’s Disease: a Case–Control Replication Study and Meta-analysis

Molecular Neurobiology

Volumn 54, Issue 2, 2017, Pages 1187-1195

  Xu, Hui Min ^a   Tan, Lin ^b   Wan, Yu ^c   Tan, Meng Shan ^c   Zhang, Wei ^c   Zheng, Zhan Jie ^d   Kong, Ling Li ^d   Wang, Zi Xuan ^c   Jiang, Teng ^e   Tan, Lan ^a,b,c   Yu, Jin Tai ^c,f  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

^c QINGDAO UNIVERSITY   (China)

^d SHANDONG MENTAL HEALTH CENTER   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer s disease; Meta analysis; Polymorphism; Progranulin; rs5848

Indexed keywords

APOLIPOPROTEIN E; GENOMIC DNA; PROGRANULIN; GRN PROTEIN, HUMAN; SIGNAL PEPTIDE;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN INTERACTION; REPLICATION STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; DNA REPLICATION; GENETIC ASSOCIATION STUDY; GENETICS; META ANALYSIS; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; DNA REPLICATION; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE;

EID: 84955590411     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9698-4     Document Type: Article

References (37)

1. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362(4):329–344. doi:10.1056/NEJMra0909142
2. Bettens K, Sleegers K, Van Broeckhoven C (2013) Genetic insights in Alzheimer’s disease. Lancet Neurol 12(1):92–104. doi:10.1016/S1474-4422(12)70259-4
3. Jiang T, Yu JT, Tian Y, Tan L (2013) Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr Alzheimer Res 10(8):852–867
4. Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer’s disease: an update. Annu Rev Neurosci 37:79–100. doi:10.1146/annurev-neuro-071013-014300
5. Jiang T, Yu JT, Zhu XC, Zhang QQ, Tan MS, Cao L, Wang HF, Lu J et al (2014) Angiotensin-(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas/eNOS-dependent pathway. Br J Pharmacol 171(18):4222–4232. doi:10.1111/bph.12770
6. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43(5):436–441. doi:10.1038/ng.801
7. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435. doi:10.1038/ng.803
8. Tan MS, Jiang T, Tan L, Yu JT (2014) Genome-wide association studies in neurology. Ann Transl Med 2(12):124. doi:10.3978/j.issn.2305-5839.2014.11.12
9. Tan L, Yu JT, Zhang W, Wu ZC, Zhang Q, Liu QY, Wang W, Wang HF et al (2013) Association of GWAS-linked loci with late-onset Alzheimer’s disease in a northern Han Chinese population. Alzheimers Dement 9(5):546–553. doi:10.1016/j.jalz.2012.08.007
10. Karch CM, Cruchaga C, Goate AM (2014) Alzheimer’s disease genetics: from the bench to the clinic. Neuron 83(1):11–26. doi:10.1016/j.neuron.2014.05.041
11. Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, Li Y, Martens LH et al (2014) Progranulin protects against amyloid beta deposition and toxicity in Alzheimer’s disease mouse models. Nat Med 20(10):1157–1164. doi:10.1038/nm.3672
12. Chen Y, Li S, Su L, Sheng J, Lv W, Chen G, Xu Z (2015) Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol 262(4):814–822. doi:10.1007/s00415-014-7630-2
13. Lee MJ, Chen TF, Cheng TW, Chiu MJ (2011) rs5848 variant of progranulin gene is a risk of Alzheimer’s disease in the Taiwanese population. Neurodegener Dis 8(4):216–220. doi:10.1159/000322538
14. Kamalainen A, Viswanathan J, Natunen T, Helisalmi S, Kauppinen T, Pikkarainen M, Pursiheimo JP, Alafuzoff I et al (2013) GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer’s disease patients. J Alzheimers Dis 33(1):23–27. doi:10.3233/jad-2012-120946
15. Viswanathan J, Makinen P, Helisalmi S, Haapasalo A, Soininen H, Hiltunen M (2009) An association study between granulin gene polymorphisms and Alzheimer’s disease in Finnish population. Am J Med Genet B Neuropsychiatr Genet 150B(5):747–750. doi:10.1002/ajmg.b.30889
16. Mateo I, Gonzalez-Aramburu I, Pozueta A, Vazquez-Higuera JL, Rodriguez-Rodriguez E, Sanchez-Juan P, Calero M, Dobato JL et al (2013) Reduced serum progranulin level might be associated with Parkinson’s disease risk. Eur J Neurol 20(12):1571–1573. doi:10.1111/ene.12090
17. Fenoglio C, Galimberti D, Cortini F, Kauwe JS, Cruchaga C, Venturelli E, Villa C, Serpente M et al (2009) Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer’s disease. J Alzheimers Dis 18(3):603–612. doi:10.3233/jad-2009-1170
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944
19. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. doi:10.1007/s10654-010-9491-z
20. He Z, Bateman A (2003) Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 81(10):600–612. doi:10.1007/s00109-003-0474-3
21. Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR et al (2010) Progranulin expression in the developing and adult murine brain. J Comp Neurol 518(19):3931–3947. doi:10.1002/cne.22430
22. Petoukhov E, Fernando S, Mills F, Shivji F, Hunter D, Krieger C, Silverman MA, Bamji SX (2013) Activity-dependent secretion of progranulin from synapses. J Cell Sci 126(Pt 23):5412–5421. doi:10.1242/jcs.132076
23. Bateman A, Bennett HP (2009) The granulin gene family: from cancer to dementia. Bioessays 31(11):1245–1254. doi:10.1002/bies.200900086
24. Kortvelyessy P, Gukasjan A, Sweeny-Reed C, Heinze HJ, Thurner L, Bittner DM (2015) Progranulin and amyloid-beta levels: relationship to neuropsychology in frontotemporal and Alzheimer’s disease. J Alzheimers Dis. doi:10.3233/jad-150069
25. D'Alton S, Lewis J (2014) Understanding the role of progranulin in Alzheimer’s disease. Nat Med 20(10):1099–1100. doi:10.1038/nm.3712
26. Sleegers K, Brouwers N, Van Broeckhoven C (2010) Role of progranulin as a biomarker for Alzheimer’s disease. Biomark Med 4(1):37–50
27. Pereson S, Wils H, Kleinberger G, McGowan E, Vandewoestyne M, Van Broeck B, Joris G, Cuijt I et al (2009) Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J Pathol 219(2):173–181. doi:10.1002/path.2580
28. Antonell A, Gil S, Sanchez-Valle R, Balasa M, Bosch B, Prat MC, Chiollaz AC, Fernandez M et al (2012) Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer’s disease: detection of GRN mutations in a Spanish cohort. J Alzheimers Dis 31(3):581–591. doi:10.3233/jad-2012-112120
29. Serpente M, Fenoglio C, Clerici F, Bonsi R, Arosio B, Cioffi SM, Rotondo E, Franceschi M et al (2015) Transmembrane protein 106B gene (TMEM106B) variability and influence on progranulin plasma levels in patients with Alzheimer’s disease. J Alzheimers Dis 43(3):757–761. doi:10.3233/jad-141167
30. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW (2007) Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 4:7. doi:10.1186/1742-2094-4-7
31. Inestrosa NC, Arenas E (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11(2):77–86. doi:10.1038/nrn2755
32. Hosokawa M, Arai T, Masuda-Suzukake M, Kondo H, Matsuwaki T, Nishihara M, Hasegawa M, Akiyama H (2015) Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. J Neuropathol Exp Neurol 74(2):158–165. doi:10.1097/NEN.0000000000000158
33. Karch CM, Jeng AT, Skorupa T, Cruchaga C, Goate AM (2013) Novel progranulin variants do not disrupt progranulin secretion and cleavage. Neurobiol Aging 34(11):2538–2540. doi:10.1016/j.neurobiolaging.2013.05.004
34. Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ et al (2008) Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 17(23):3631–3642. doi:10.1093/hmg/ddn257
35. Hsiung GY, Fok A, Feldman HH, Rademakers R, Mackenzie IR (2011) rs5848 polymorphism and serum progranulin level. J Neurol Sci 300(1–2):28–32. doi:10.1016/j.jns.2010.10.009
36. Dickson DW, Baker M, Rademakers R (2010) Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis 7(1–3):170–174. doi:10.1159/000289231
37. Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M et al (2008) Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71(9):656–664. doi:10.1212/01.wnl.0000319688.89790.7a